Literature DB >> 25861023

Microfoci of malignant progression in diffuse low-grade gliomas: towards the creation of an intermediate grade in glioma classification?

Zoé Pedeutour-Braccini1, Fanny Burel-Vandenbos, Catherine Gozé, Coralie Roger, Audrey Bazin, Valérie Costes-Martineau, Hugues Duffau, Valérie Rigau.   

Abstract

Low-grade gliomas (GII) inescapably progress to high-grade gliomas (GIII). The duration of this transition is highly variable between patients and reliable predictive markers do not exist. We noticed in a subset of cases of GII, obtained by awake neurosurgery, the presence of microfoci with high cellular density, high vascular density, or minimal endothelial proliferation, which we called GII+. Our aim was to investigate whether these foci display immunohistochemical and molecular characteristics similar to GIII and whether their presence is correlated to poor prognosis. We analyzed cell proliferation, hypoxia, vascularization, and alterations of tumorigenic pathways by immunohistochemistry (Ki-67, CD31, HIF-1-alpha, EGFR, P-AKT, P53, MDM2) and fluorescence in situ hybridization (EGFR, MDM2, PDGFRA) in the hypercellular foci of 16 GII+ cases. We compared overall survival between GII, GII+, and GIII. Ki-67, and CD31 expression was higher in the foci than in the tumor background in all cases. Aberrant expression of protein markers and genomic aberrations were also observed in some foci, distinct from the tumor background. Survival was shorter in GII+ than in GII cases. Our results suggest that these foci are the early histological hallmark of anaplastic transformation, which is supported by molecular aberrations. Our study is the first to demonstrate intratumoral morphological, immunohistochemical, and molecular heterogeneity in resection specimens of GII, the presence of which is correlated to shorter survival. Our findings question the discriminative capacity of the current glioma classification and provide arguments in favor of the creation of a grade intermediate between GII and GIII, to optimize the treatment strategy of GII.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25861023     DOI: 10.1007/s00428-014-1712-5

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  26 in total

1.  Expression and significance of P53 protein and MDM-2 protein in human gliomas.

Authors:  An-Liu Wang; Zhao-Xia Liu; Guang Li; Li-Wei Zhang
Journal:  Chin Med J (Engl)       Date:  2011-08       Impact factor: 2.628

2.  Expression of pERK and pAKT in human astrocytomas: correlation with IDH1-R132H presence, vascular endothelial growth factor, microvascular characteristics and clinical outcome.

Authors:  Angelica A Saetta; Georgia Levidou; Elias A El-Habr; Ioannis Panayotidis; Vassilis Samaras; Irene Thymara; Stratigoula Sakellariou; Efstathios Boviatsis; Efstratios Patsouris; Penelope Korkolopoulou
Journal:  Virchows Arch       Date:  2011-04-15       Impact factor: 4.064

Review 3.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

4.  Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response.

Authors:  Nicholas J Szerlip; Alicia Pedraza; Debyani Chakravarty; Mohammad Azim; Jeremy McGuire; Yuqiang Fang; Tatsuya Ozawa; Eric C Holland; Jason T Huse; Suresh Jhanwar; Margaret A Leversha; Tom Mikkelsen; Cameron W Brennan
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-08       Impact factor: 11.205

5.  PDGFRA gain in low-grade diffuse gliomas.

Authors:  Kazuya Motomura; Michel Mittelbronn; Werner Paulus; Benjamin Brokinkel; Kathy Keyvani; Ulrich Sure; Karsten Wrede; Yoichi Nakazato; Yuko Tanaka; Naosuke Nonoguchi; Daniela Pierscianek; Young-Ho Kim; Luigi Mariani; Anne Vital; Arie Perry; Hiroko Ohgaki
Journal:  J Neuropathol Exp Neurol       Date:  2013-01       Impact factor: 3.685

6.  Prevalence, clinico-pathological value, and co-occurrence of PDGFRA abnormalities in diffuse gliomas.

Authors:  Agustí Alentorn; Yannick Marie; Catherine Carpentier; Blandine Boisselier; Marine Giry; Marianne Labussière; Karima Mokhtari; Khê Hoang-Xuan; Marc Sanson; Jean-Yves Delattre; Ahmed Idbaih
Journal:  Neuro Oncol       Date:  2012-10-16       Impact factor: 12.300

7.  A different view on DNA amplifications indicates frequent, highly complex, and stable amplicons on 12q13-21 in glioma.

Authors:  Ulrike Fischer; Andreas Keller; Petra Leidinger; Stephanie Deutscher; Sabrina Heisel; Steffi Urbschat; Hans-Peter Lenhof; Eckart Meese
Journal:  Mol Cancer Res       Date:  2008-04       Impact factor: 5.852

8.  Preoperative dynamic contrast-enhanced MRI correlates with molecular markers of hypoxia and vascularity in specific areas of intratumoral microenvironment and is predictive of patient outcome.

Authors:  Randy L Jensen; Michael L Mumert; David L Gillespie; Anita Y Kinney; Matthias C Schabel; Karen L Salzman
Journal:  Neuro Oncol       Date:  2013-12-04       Impact factor: 12.300

9.  Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

Authors:  Fred R Hirsch; Marileila Varella-Garcia; Paul A Bunn; Michael V Di Maria; Robert Veve; Roy M Bremmes; Anna E Barón; Chan Zeng; Wilbur A Franklin
Journal:  J Clin Oncol       Date:  2003-09-02       Impact factor: 44.544

10.  Dynamic 18F-FET PET in newly diagnosed astrocytic low-grade glioma identifies high-risk patients.

Authors:  Nathalie L Jansen; Bogdana Suchorska; Vera Wenter; Sabina Eigenbrod; Christine Schmid-Tannwald; Andreas Zwergal; Maximilian Niyazi; Mark Drexler; Peter Bartenstein; Oliver Schnell; Jörg-Christian Tonn; Niklas Thon; Friedrich-Wilhelm Kreth; Christian la Fougère
Journal:  J Nucl Med       Date:  2013-12-30       Impact factor: 10.057

View more
  9 in total

1.  Biopsy targeting with dynamic contrast-enhanced versus standard neuronavigation MRI in glioma: a prospective double-blinded evaluation of selection benefits.

Authors:  Vera C Keil; Bogdan Pintea; Gerrit H Gielen; Susanne Greschus; Rolf Fimmers; Jürgen Gieseke; Matthias Simon; Hans H Schild; Dariusch R Hadizadeh
Journal:  J Neurooncol       Date:  2017-04-19       Impact factor: 4.130

2.  Imaging-Based Algorithm for the Local Grading of Glioma.

Authors:  E D H Gates; J S Lin; J S Weinberg; S S Prabhu; J Hamilton; J D Hazle; G N Fuller; V Baladandayuthapani; D T Fuentes; D Schellingerhout
Journal:  AJNR Am J Neuroradiol       Date:  2020-02-06       Impact factor: 3.825

3.  Effect and molecular mechanism of mTOR inhibitor rapamycin on temozolomide-induced autophagic death of U251 glioma cells.

Authors:  Bing Li; Chun Zhou; Liang Yi; Lunshan Xu; Minhui Xu
Journal:  Oncol Lett       Date:  2017-12-06       Impact factor: 2.967

4.  Expression of TYMS in lymph node metastasis from low-grade glioma.

Authors:  Bingqian Ding; Ming Gao; Zhenjiang Li; Chenyang Xu; Shaokang Fan; Weiya He
Journal:  Oncol Lett       Date:  2015-06-24       Impact factor: 2.967

5.  Identification of CRYAB+ KCNN3+ SOX9+ Astrocyte-Like and EGFR+ PDGFRA+ OLIG1+ Oligodendrocyte-Like Tumoral Cells in Diffuse IDH1-Mutant Gliomas and Implication of NOTCH1 Signalling in Their Genesis.

Authors:  Meera Augustus; Donovan Pineau; Franck Aimond; Safa Azar; Davide Lecca; Frédérique Scamps; Sophie Muxel; Amélie Darlix; William Ritchie; Catherine Gozé; Valérie Rigau; Hugues Duffau; Jean-Philippe Hugnot
Journal:  Cancers (Basel)       Date:  2021-04-27       Impact factor: 6.639

6.  Optimizing prognosis-related key miRNA-target interactions responsible for cancer metastasis.

Authors:  Hongying Zhao; Huating Yuan; Jing Hu; Chaohan Xu; Gaoming Liao; Wenkang Yin; Liwen Xu; Li Wang; Xinxin Zhang; Aiai Shi; Jing Li; Yun Xiao
Journal:  Oncotarget       Date:  2017-11-27

Review 7.  The Concept of «Peritumoral Zone» in Diffuse Low-Grade Gliomas: Oncological and Functional Implications for a Connectome-Guided Therapeutic Attitude.

Authors:  Melissa Silva; Catalina Vivancos; Hugues Duffau
Journal:  Brain Sci       Date:  2022-04-15

8.  Multivariate Analysis of RNA Chemistry Marks Uncovers Epitranscriptomics-Based Biomarker Signature for Adult Diffuse Glioma Diagnostics.

Authors:  S Relier; A Amalric; A Attina; I B Koumare; V Rigau; F Burel Vandenbos; D Fontaine; M Baroncini; J P Hugnot; H Duffau; L Bauchet; C Hirtz; E Rivals; A David
Journal:  Anal Chem       Date:  2022-08-23       Impact factor: 8.008

9.  Transformation Foci in IDH1-mutated Gliomas Show STAT3 Phosphorylation and Downregulate the Metabolic Enzyme ETNPPL, a Negative Regulator of Glioma Growth.

Authors:  N Leventoux; M Augustus; S Azar; S Riquier; J P Villemin; S Guelfi; L Falha; L Bauchet; C Gozé; W Ritchie; T Commes; H Duffau; V Rigau; J P Hugnot
Journal:  Sci Rep       Date:  2020-03-26       Impact factor: 4.996

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.